SPRY: ARS Pharma Company Value to Net Income

Corporate emblem and logo of ARS Pharmaceuticals Inc (SPRY)

ARS Pharmaceuticals is developing Neffy, an innovative epinephrine nasal spray that replaces painful injections. The company's adjusted P/E reflects the asset's value dynamics, where the value -1.60 describes the current level. The needle-free delivery format positions the product as an unrivaled leader, enhancing patient comfort. The uniqueness of the solution provides exceptional pricing power and the approval of premium rates by insurance organizations.

SPRY ARS Corp: Price to Earnings Ratio in the range 04/28/2023 - 11/10/2026

Comprehensive metric breakdowns and analytics for ARS Pharma (SPRY)

- price and consensus price forecast:
Stock Price ars-pharma.com|SPRY - Consensus Target
- market capitalization information:
Market Value ARS Pharmaceuticals, Inc.|SPRY - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share ARS Pharmaceuticals|SPRY - Company Net Assets|Market Cap to Book Value Multiple ars-pharma.com|SPRY - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio ARS Pharmaceuticals|SPRY - Long-Term Debt to Capital|Current Liabilities to Capital ARS Corp|SPRY - Company Debts|Debt to Net Assets Ratio ARS Pharmaceuticals, Inc.|SPRY - Company Long-Term Debts|Company Short-Term Debts ARS Pharmaceuticals|Intermediate Coverage Ratio ars-pharma.com
- business earnings and investment ratios data:
SPRY - Company Net Income|Company Profit Forecast ARS Pharmaceuticals|SPRY - Price to Earnings Ratio|Future Price to Earnings Multiple ARS Pharmaceuticals Inc|SPRY - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio ARS Pharmaceuticals, Inc.|SPRY - Operating profit EBITDA|Earnings per share for the trailing year ARS Pharmaceuticals|SPRY - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ars-pharma.com|SPRY - Earnings per share growth in current year|Expected earnings per share trend next year ARS Pharmaceuticals
Comprehensive company analysis:ars-pharma.com - SPRY
Flagship merchandise of ARS Pharmaceuticals, Inc.

Investors must determine the fair value of an asset by comparing market capitalization with the business's actual ability to generate net income. This calculated price-to-earnings multiple measures the investment payback period, which in the case of ARS Pharmaceuticals (SPRY) is supported by rapid revenue growth from the introduction of the innovative drug neffy, transforming the company's fundamental valuation through commercial expansion.

Key competitors

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|P/E Multiple PCRX (Pacira BioSciences, Inc.)|P/E Multiple Theravance Biopharma Inc TBPH|AQST - Price to Earnings Ratio|Company Value to Net Income SCPH (scPharmaceuticals Inc.)|tectonictx.com (TECX) - Price to Earnings Ratio|TNXP - Business Payback Period|Price to Earnings Ratio SXTC|EPRX: Company Value to Net Income|Price to Earnings Ratio BioHarvest (BHST)|EXOZ: Market Cap to Net Income|P/E Multiple ORMP (Oramed Pharmaceuticals Inc.)|Company Value to Net Income ENTX|MindWalk Holdings Inc. - P/E Multiple|ABVC - P/E Multiple|Cumberland Pharma (CPIX) - Price to Earnings Ratio|Quantum BioPharma Corp - Company Value to Net Income|Price to Earnings Ratio FibroGen, Inc.|Price to Earnings Ratio telomirpharma.com (TELO)|P/E Multiple RANI|P/E Multiple synergychc.com (SNYR)|P/E Multiple RLYB (Rallybio)|LEXX - Price to Earnings Ratio|Pulmatrix, Inc. - P/E Multiple|Market Cap to Earnings Pheton Holdings Ltd|APM (aptorumgroup.com) - Price to Earnings Ratio|Lyra Therapeutics Inc. (LYRA) - P/E Multiple|Price to Earnings Ratio IBO|TNFA (TNF Pharma) - Market Price to Net Income Ratio|P/E Multiple YCBD|Business Payback Period painreform.com|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|LIPO - Price to Earnings Ratio|Optinose - P/E Multiple|PIRS - P/E Multiple|Procaps Group S.A. (PROC) - Price to Earnings Ratio|PTPI (petrospharma.com) - Price to Earnings Ratio|Price to Earnings Ratio Qilian International Holding|Acelyrin Inc. (SLRN) - Business Payback Period|Price to Earnings Ratio TFF Pharma (TFFP)